Lung neoplasm

This phase 1 trial tests a new type of CAR-T cell therapy designed to target a protein called DLL3 found on small cell lung cancer cells. The CAR-T cells are also modified to boost their activity through PD-L1 and 4-1BB signals. The study enrolls adults with relapsed or refractor…

This phase III trial is testing whether a precise, high-dose radiation technique called stereotactic radiosurgery (SRS) is better at preserving memory and thinking than the current standard of whole brain radiation that avoids the hippocampus (the brain's memory center) plus a dr…

This trial is testing whether combining two immunotherapy drugs, cemiplimab and dupilumab, can safely and effectively shrink tumors in people with early-stage, operable non-small cell lung cancer. Participants receive both drugs before their scheduled surgery, and researchers wil…

This study tests a new medicine called PF-08634404, given alone or with chemotherapy, for adults with early or locally advanced non-small cell lung cancer. The trial has three parts: before surgery, after surgery if cancer remains, or after chemoradiation. Researchers will check …

This Phase 2 trial tests the drug alisertib in 120 people with extensive stage small cell lung cancer that has worsened after standard treatments like chemotherapy and immunotherapy. The goal is to see if alisertib can shrink tumors or slow the disease, and to identify which pati…

This Phase 3 trial tests whether adding the targeted drug calderasib to the immunotherapy pembrolizumab helps people with a specific KRAS G12C-mutated lung cancer live longer without their cancer growing. About 675 participants with advanced non-squamous non-small cell lung cance…

This phase 3 trial tests whether adding a precise, high-dose radiation treatment (SBRT) to standard chemoradiation and immunotherapy improves survival for people with locally advanced non-small cell lung cancer that cannot be surgically removed. About 474 participants will be ran…

This Phase 3 trial tests ZL-1310, a drug that delivers chemotherapy directly to cancer cells, in people with small cell lung cancer that has returned after initial treatment. About 480 participants will receive either ZL-1310 or one of three standard treatments. The study aims to…

This early-stage study tests a new medicine called PF-08046033 in adults with advanced lung, esophageal, or skin cancers that have spread or can't be removed. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug may he…

This study tests a new drug called BMS-986340, alone or with other cancer treatments, in people with advanced solid tumors like lung, colon, or breast cancer. The goal is to find safe doses and check for side effects. About 1,100 adults with tumors that have worsened after standa…

This early-stage study tests a new oral drug, APR-1051, in about 90 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also look for early signs that the drug might…

This phase 3 trial tests whether adding the targeted pill calderasib (MK-1084) to the immunotherapy durvalumab helps people with a specific KRAS G12C-mutated lung cancer live longer without their cancer growing. About 310 participants who have finished chemotherapy and radiation …

This study tests a new drug called AI-081 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is a bispecific antibody that targets two proteins (PD-1 and VEGF) involved in cancer growth and immune evasion. The trial has two phases: fir…

This phase 3 trial is testing whether a combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy works better than the current standard (pembrolizumab plus chemotherapy) for people with advanced non-squamous lung cancer whose tumors have PD-L1 levels of…

This early-phase study tests gilteritinib, a drug already approved for a type of leukemia, in about 40 adults with ALK-positive non-small cell lung cancer whose tumors no longer respond to standard ALK inhibitors. Participants take gilteritinib tablets daily in 28-day cycles. The…

This phase III trial tests whether proton craniospinal irradiation (pCSI) can improve survival compared to standard involved-field radiation therapy (IFRT) for patients with breast or non-small cell lung cancer that has spread to the lining of the brain and spinal cord (leptomeni…

This study tests a new medicine called PF-08634404 given with chemotherapy for adults with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. The trial has two parts: first checking safety, then comparing the new combo to an approved treatment (atezoli…

This phase 2 trial tests whether a patient's own white blood cells, genetically modified in a lab to recognize and attack their specific tumor mutations, can shrink metastatic cancers. Participants include people with several advanced solid tumors or multiple myeloma who have exh…

This trial tests whether two approved drugs, dabrafenib and trametinib, can treat rare cancers that have a specific genetic change called BRAF V600. These drugs are already used for melanoma and lung cancer, but researchers want to see if they help people with other cancer types.…

This phase 3 trial tests whether a personalized mRNA cancer vaccine (intismeran) alone or combined with an immunotherapy drug (pembrolizumab) can prevent non-small cell lung cancer from coming back after complete surgical removal. About 876 people with high-risk stage I lung canc…

This early-stage trial is testing an investigational drug called GIM-122 in adults with advanced solid tumors that have not responded to standard treatments, including PD-1/PD-L1 inhibitors. GIM-122 is a special antibody designed to fight cancer in two ways. The study aims to fin…

This Phase III trial tests whether giving radiation in three smaller doses (FSRS) works better than a single large dose (SRS) for cancer that has spread to the brain. About 269 adults with lung, breast, melanoma, kidney, or gastrointestinal cancers will be randomly assigned to on…

This study tests whether a new drug combination (BMS-986489) works better than the current standard (durvalumab) as follow-up treatment after chemoradiation for limited-stage small cell lung cancer. About 250 adults whose cancer hasn't spread widely will be randomly assigned to o…

This study tests personalized radiotherapy approaches for people with lung cancer, brain metastases, or other solid tumors. It aims to see if adapting radiation based on how a patient responds is safe and effective. About 45 adults will participate, receiving either extra radiati…

This early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…

This study tests two experimental drugs, gocatamig and ifinatamab deruxtecan, alone or with standard chemotherapy and immunotherapy, for people with extensive-stage small cell lung cancer. The goal is to see if the combination is safe and can shrink tumors. About 170 participants…

This study compares an experimental drug (PF-08046054) to standard chemotherapy (docetaxel) in about 680 adults with advanced PD-L1 positive non-small cell lung cancer that has worsened after prior treatments. Participants are randomly assigned to receive one of the two drugs by …

This phase 3 trial is testing whether the immunotherapy drug durvalumab, given after surgery, can prevent early-stage non-small cell lung cancer from coming back. About 306 participants who have had their tumor completely removed will be randomly assigned to receive durvalumab or…

This early-stage trial is testing an experimental drug called SIM0505 in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug shrinks tumors. About 414 participants will re…

This study tests whether adding the experimental drug obrixtamig to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer. About 670 adults with extensive-stage disease will be randomly assigned to receive either the new combination…

This study tests whether a new experimental drug called PF-08634404, given with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemo) for adults with advanced non-small cell lung cancer. About 1,410 participants will be randomly assigned to rec…

This study is exploring whether giving radiotherapy at the same time as immunotherapy and chemotherapy, versus giving it after, works better as a first treatment for extensive-stage small cell lung cancer. The trial will enroll about 60 adults with this advanced cancer. Participa…

This study tests a new medicine called PF-08634404 given with chemotherapy for adults with transformed small cell lung cancer (T-SCLC), a rare and aggressive cancer that develops from another lung cancer type. About 40 participants will receive the drug combo through IV infusions…

This study tests a new drug called TUB-040 for people with ovarian cancer that no longer responds to platinum chemotherapy, or with a type of lung cancer that has come back. TUB-040 is an antibody-drug conjugate, meaning it delivers a powerful chemotherapy directly to cancer cell…

This Phase 3 trial tests whether adding an experimental mRNA vaccine (V940) to standard immunotherapy (Keytruda) can prevent non-small cell lung cancer from coming back after surgery. About 868 people with stage II-IIIB lung cancer who have had their tumors completely removed wil…

This Phase 3 trial is testing whether adding an experimental drug called calderasib (MK-1084) to standard immunotherapy (pembrolizumab) can keep non-small cell lung cancer from returning after surgery. The study enrolls 400 people with a specific KRAS G12C mutation whose cancer w…

This study tests an experimental drug called SHR-4610 in 258 adults with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The trial has two phases: first, finding the safest dose, and second, checking how well the drug shrinks…

This study tests a new drug called YH42946 in people with advanced solid tumors that have certain gene changes (HER2 or EGFR). The main goals are to check safety and see if the drug shrinks tumors. About 161 adults who have run out of standard options will take part.

This trial tests a new drug called TUB-030 in adults with advanced solid tumors, including head and neck, lung, and breast cancers. The goal is to find the safest and most effective dose. Participants receive the drug every three weeks and are monitored for side effects and tumor…

This phase 2 trial is testing a type of radiation called craniospinal irradiation that avoids the hippocampus, a brain area key for memory. It is for people with breast or lung cancer that has spread to the fluid and lining around the brain and spinal cord. The goal is to see if …

This phase 2 study tests an investigational drug called telisotuzumab adizutecan in about 100 people aged 12 and older with advanced solid tumors that have a specific genetic change (MET amplification). The drug is given through an IV and aims to shrink tumors or stop them from g…

This study tests whether adjusting common over-the-counter medications can make immune checkpoint inhibitors work better for people with solid tumors. Participants are asked to avoid acetaminophen and cannabis/THC/CBD, while taking aspirin and loratadine (or similar antihistamine…

This early-phase trial is testing an experimental oral drug called GIM-531, alone or with an immunotherapy (anti-PD-1), in 117 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe, tolerable, and can help th…

This study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.

This study tests a new drug called ABBV-706 combined with the immunotherapy atezolizumab as a first treatment for people with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. About 180 adults will receive either the new combination at one of two dose…

This early-phase study is testing a new oral drug called BG-75202, alone or with other medications, in people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and …

This early-stage trial tests a new drug called CS5007 in people with advanced solid tumors that cannot be removed by surgery. The drug is designed to seek out and attack cancer cells while sparing healthy ones. The study will first find the safest dose and then check if the drug …

This study tests a new drug called rilvegostomig against the standard drug pembrolizumab, both given with chemotherapy, as a first treatment for people with advanced non-squamous lung cancer that has spread. About 878 adults whose tumors have a specific protein (PD-L1) will take …

This phase 3 trial is testing a new combination of drugs (BMS-986489) plus chemotherapy against a standard treatment (atezolizumab plus chemotherapy) for people with extensive-stage small cell lung cancer, a fast-growing cancer. The study aims to see if the new combo helps people…

This study tests a new drug called telisotuzumab adizutecan (ABBV-400) combined with an immunotherapy drug (budigalimab or pembrolizumab) in people with advanced non-squamous lung cancer who have not had prior treatment. The goal is to find the best dose that is safe and effectiv…

This early-stage study tests a new tablet called GW01-200 in 100 people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participan…

This study looks at whether giving radiation to the chest after surgery and chemo-immunotherapy can help people with stage III non-small cell lung cancer who still have signs of cancer after treatment. About 118 adults will be randomly assigned to receive or not receive radiation…

This phase 2 trial is testing a combination of three drugs—datopotamab deruxtecan, carboplatin, and pembrolizumab—in 46 people with non-small cell lung cancer that has spread to the brain and who have not had prior treatment for those brain tumors. The goal is to see how well the…

This early-stage trial tests two experimental pills (PF-07799544 and PF-07799933) taken twice daily at home by adults with advanced solid tumors that have a specific gene change called BRAF V600. The study aims to find safe doses and see if the drugs can shrink tumors. About 124 …

This phase 3 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy after surgery can help prevent non-small cell lung cancer from coming back. About 1,210 people with stage II to IIIB lung cancer will receive either chemo plus pembrolizumab toge…

This study tests whether adding the drug MK-2870 to standard immunotherapy (pembrolizumab) after surgery can help prevent lung cancer from coming back. It is for people with stage II to IIIB non-small cell lung cancer whose tumor did not fully disappear after chemotherapy and imm…

This phase 2 trial is testing three different doses of an investigational drug called telisotuzumab vedotin in about 150 adults with a specific type of advanced lung cancer (non-small cell lung cancer that has high levels of a protein called c-Met and no EGFR mutation). The drug …

This phase III trial is testing whether the immunotherapy drug atezolizumab, given after surgery, can prevent stage I non-small cell lung cancer from returning. About 336 patients who have had their tumor completely removed will be randomly assigned to receive either atezolizumab…

This phase 3 trial tests whether adding the targeted drug adagrasib to standard immunotherapy and chemotherapy can help people with a specific genetic subtype of advanced lung cancer (KRAS G12C mutation) live longer without their cancer growing. About 630 adults who have not had …

This study tests a new drug, ABBV-706, against standard treatments for small cell lung cancer that has come back or stopped responding. About 531 adults will receive either ABBV-706 or usual care (topotecan, lurbinectedin, or amrubicin) to see which works better. The goal is to s…

This early-phase trial tests a new drug called MRG007 (ARR-217) in people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check if the drug can shrink tumors. About 405 participants with colorectal, gastric, or pan…

This study tests a new therapy where a person's own white blood cells are collected, genetically modified in a lab to recognize and attack cancer cells with a specific mutation (KRAS G12V), and then infused back. Participants also receive chemotherapy and a drug to boost cell act…

This phase II trial tests two drugs, lurbinectedin and avelumab, in people with a rare and aggressive bladder cancer called small cell carcinoma. Participants who have already had a drug like avelumab will receive only lurbinectedin; others will get both. The study aims to see if…

This early-stage trial tests a new drug called YL211 in 155 people with advanced solid tumors who have no standard treatment options left. The study has three parts: first, finding a safe dose; then, confirming that dose; and finally, testing how well it works. The main goals are…

This study tests whether adding the experimental drug TRC102 to standard treatment (chemotherapy, radiation, and immunotherapy) can help shrink tumors and extend survival in people with stage III non-squamous lung cancer. TRC102 blocks cancer cells from repairing damage, making t…

This study tests whether a daily pill called zongertinib can help prevent lung cancer from coming back in people with early-stage (Stage II-IIIB) non-small cell lung cancer that has a specific HER2 mutation. All participants have had surgery to remove their tumor and standard che…

This early-phase trial tests the safety of CRD3874-SI, a drug that activates the STING pathway to boost the immune system against cancer. About 81 adults with advanced solid tumors (sarcoma, Merkel cell carcinoma, and others) will receive weekly IV infusions at increasing doses. …

This early-phase study tests CBX-12 in about 35 adults with advanced solid tumors that have spread and stopped responding to prior treatments. CBX-12 works by entering cancer cells and damaging their DNA, which can kill the cells. Researchers will measure how well the drug trigge…

This study tests a new daily pill, firmonertinib, against standard chemotherapy for people with advanced non-small cell lung cancer that has certain EGFR mutations (PACC or L861Q). About 300 participants will be randomly assigned to receive either the pill or chemo. The goal is t…

This phase 2 trial is testing two experimental drugs, ubamatamab and REGN7075, alone or together, in 300 people with advanced or metastatic non-small cell lung cancer who have already had standard treatments. A third drug, sarilumab, may be used to manage immune-related side effe…

This study tests OTP-01, a new drug that targets two cancer pathways (PD-1 and VEGFR2) at once, in 170 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the best dose, check safety, and see if the drug can shrink tum…

This study tests a new drug called GTAEXS617 in people with advanced solid tumors (like lung, pancreatic, or ovarian cancer) that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 230 p…

This study tests whether a new drug combo (sotorasib plus chemotherapy) works better than the current standard (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer that has a specific KRAS G12C gene change and low PD-L1 levels. About 750 adults wh…

This trial tests whether taking firmonertinib after surgery can help prevent non-small cell lung cancer from coming back in people with certain uncommon EGFR mutations. Participants who had their tumor completely removed will receive either firmonertinib or a placebo daily. The s…

This early-stage study tests a new tablet, AST2303, in 120 people with advanced non-small cell lung cancer that has spread. The main goals are to check the drug's safety and find the right dose, while also seeing if it can shrink tumors or slow the disease. Participants will take…

This phase 3 study compares two immunotherapy drugs—rilvegostomig and pembrolizumab (Keytruda)—each combined with standard chemotherapy, as a first treatment for people with advanced squamous non-small cell lung cancer that has a specific protein (PD-L1). About 880 participants w…

This early-phase trial is testing whether combining two experimental drugs, JAB-21822 and JAB-3312, can safely shrink or control advanced solid tumors that carry a specific KRAS G12C mutation. The study includes people with cancers like non-small cell lung, colorectal, or pancrea…

This early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…

This Phase III trial is testing whether adding bevacizumab to the standard drug osimertinib can better control advanced EGFR-mutant non-small cell lung cancer. About 300 people with stage IIIB or IV disease will be randomly assigned to receive either the combination or osimertini…

This study takes white blood cells from a patient's lung tumor, grows them in large numbers in the lab, and gives them back to the patient to fight the cancer. The goal is to see if these specially selected cells can shrink tumors in people with advanced non-small cell lung cance…

This trial is testing an oral drug called JAB-21822 in people with advanced or metastatic non-small cell lung cancer (NSCLC) that has a KRAS G12C mutation along with an STK11 mutation. The study aims to see if the drug is safe, tolerable, and effective in shrinking tumors. Partic…

This phase III trial compares adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in adults aged 70+ with advanced non-small cell lung cancer. The goal is to see if the combination improves survival. About 304 participants will be enrolled.

This study tests whether a new drug called furmonertinib, given with chemotherapy, works better than the current standard drug osimertinib for people with a specific type of lung cancer (EGFR-mutant non-squamous NSCLC) that has spread to the brain. About 380 adults whose cancer h…

This phase II trial tests whether a radioactive drug called lutetium Lu 177 dotatate works better than the usual drug everolimus for people with advanced bronchial neuroendocrine tumors (a type of lung cancer). The radioactive drug targets a protein on tumor cells and delivers ra…

This trial is testing whether the drug furmonertinib can help prevent non-small cell lung cancer from coming back after surgery. The study enrolls adults with stage II-IIIA lung cancer that has specific EGFR mutations and who have had the tumor completely removed, with or without…

This phase 3 trial is investigating whether a combination of two oral drugs, JAB-21822 and JAB-3312, can work better than the current standard treatment (immunotherapy plus chemotherapy) as a first-line therapy for people with advanced non-squamous non-small cell lung cancer that…

This study tests a new drug, BNT327, combined with chemotherapy and other agents in people with advanced non-small cell lung cancer who have not had prior treatment. The trial will enroll about 1,260 participants across multiple sites worldwide. The goal is to see if the combinat…

This study is the first time the drug BNT3214 is being tested in people. It aims to find a safe and effective dose for adults with advanced solid tumors. The trial has three parts: first, finding the best dose; then, testing it in different cancer types. About 533 participants wi…

This study tests an experimental drug called SMP-3124LP, which is a liposomal (fat-encapsulated) version of a cancer-fighting compound. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding the safest d…

This study compares the standard drug osimertinib alone versus osimertinib plus chemotherapy (carboplatin and pemetrexed) in people with metastatic EGFR-mutant lung cancer who still have detectable cancer DNA in their blood after starting osimertinib. The goal is to see if the co…

This trial tests an experimental oral drug called TT-702 in people with advanced solid tumors. The drug works by blocking a protein that tumors use to hide from the immune system. The study aims to find the safest dose of TT-702 when given alone and in combination with an immunot…

This early-phase study tests a combination of two drugs (BMS-986504 and olaparib) in adults with advanced solid tumors that have lost a gene called MTAP. The main goal is to find safe doses and understand side effects. About 36 people will take part, and the study is currently re…

This study tests whether adding a new drug called cirtuvivint to standard chemotherapy can help people with small cell lung cancer that has come back after initial treatment. About 42 adults whose cancer has progressed after at least one prior therapy will receive the combination…

This early-stage study tests a new drug called FP008 in 108 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look at how the drug works in the body and whether…

This phase 3 trial tests whether the drug sacituzumab govitecan (Trodelvy) helps people with extensive stage small cell lung cancer live longer compared to standard treatments. About 695 participants who have already had one round of chemotherapy will be randomly assigned to rece…

This early-phase study tests a new treatment called MQ710, a modified virus injected directly into tumors, alone or with the immunotherapy drug pembrolizumab. It is for people with advanced solid tumors (like skin cancer or head and neck cancer) that have not responded to standar…

This Phase 3 trial is testing whether a combination of two drugs, datopotamab deruxtecan (Dato-DXd) and rilvegostomig, works better than the current standard treatment pembrolizumab for people with advanced non-squamous lung cancer that has high PD-L1 levels. About 675 participan…

This early-stage trial tests a new drug called COM503, alone or with another drug zimberelimab, in 200 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. It is a first-in-human study, so effe…

This phase II trial is testing whether a combination of two drugs, SKB264 and SKB118, can safely shrink tumors in people with advanced non-small cell lung cancer that has spread. The study includes a dose-finding phase and an expansion phase to better understand the treatment's e…

This early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…

This trial is testing whether adding radiation to the chest can help people with extensive-stage small-cell lung cancer, a type of lung cancer that has spread widely. Participants first receive standard chemotherapy plus an immunotherapy drug, and if their cancer does not worsen,…

This study tests a new drug called AZD8205, alone or with another drug (rilvegostomig), in people with advanced solid tumors like breast, ovarian, and lung cancers. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 460 adults whose c…

This study tests a new oral drug, BAY 2927088, for people with advanced non-small cell lung cancer that has specific EGFR or HER2 mutations. The trial has four parts to find the safest dose and see if the drug shrinks tumors. About 400 participants will take the drug daily until …

This early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …

This trial is for people with extensive-stage small cell lung cancer who have completed initial chemotherapy plus immunotherapy and have stable or improved disease. Participants are randomly assigned to receive either standard immunotherapy alone or immunotherapy combined with in…

This early-phase study tests a new drug called DS-3939a in about 540 people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety and see if the drug shrinks tumors. Participants must have measurable disease and good organ function.

This trial tests an experimental drug called STAR0602, which is designed to help the immune system attack cancer cells. It is being studied in people with advanced solid tumors that have not responded to standard treatments. The drug is given alone or combined with chemotherapy, …

This early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …

This study is testing a new way to find and treat several types of advanced solid tumors, including kidney, pancreatic, and colorectal cancers. It uses a special radioactive compound that attaches to a protein found on these cancer cells. The study has multiple parts: first, to s…

This early-phase study tests a new treatment called TNhYP218 CAR T cells for people with solid tumors that have high levels of a protein called mesothelin, including mesothelioma. Participants' own immune cells are collected, modified in a lab to better attack cancer, and then gi…

This early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…

This trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …

This early-phase study tests whether combining valemetostat with atezolizumab is safe as maintenance therapy for people with extensive-stage small cell lung cancer. Researchers will try different doses of valemetostat to find the best one with few side effects. The study involves…

This study tests a new combination of two drugs—gemcitabine (chemotherapy) and ivonescimab (a targeted therapy)—in people with advanced non-small cell lung cancer whose disease got worse after standard immunotherapy. The goal is to see if this combination can shrink tumors or sto…

This early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…

This study tests different drug combinations in people with early-stage non-small cell lung cancer that can be removed with surgery. The drugs are chosen based on specific genetic markers in each person's tumor. The goal is to see if these treatments shrink the tumor before surge…

This early-phase trial is testing a combination of two drugs—izalontamab brengitecan (given by IV) and adagrasib (a pill)—in 18 adults with advanced KRAS G12C-mutant non-small cell lung cancer that has stopped responding to other treatments. The main goal is to check safety and s…

This study tests whether giving immunotherapy (Cemiplimab) along with chemotherapy (Carboplatin and Paclitaxel) before radiation can help elderly or unfit patients with stage III non-small cell lung cancer live longer without their cancer getting worse. The trial will enroll 152 …

This early-phase trial is testing a new drug called BMS-986517 in about 315 adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that the drug …

This early-phase study tests a new drug called HLX3902 in about 48 people with advanced prostate cancer or other solid tumors that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. The drug is designed to help the …

This trial tests an experimental daily pill, VS-7375, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12D. Participants must have already tried chemotherapy and an immunotherapy drug. The study looks at whether the drug can shri…

This phase 3 trial tests a new daily pill, GFH375, against standard chemotherapy (docetaxel) in 300 people with advanced KRAS G12D lung cancer that has worsened after prior treatments. The drug is designed to block the specific cancer-driving mutation. Participants are randomly a…

This phase 3 study compares the experimental drug pumitamig to the standard treatment durvalumab in people with stage III lung cancer that cannot be removed by surgery. Participants must have finished chemoradiation without their cancer getting worse. The main goal is to see if p…

This extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …

This study tests whether adding the experimental drug visugromab to standard chemotherapy and immunotherapy can shrink tumors better than standard treatment alone in people with advanced non-squamous lung cancer that has not been treated before. About 107 adults with newly diagno…

This early-stage trial tests IM-1021, an antibody-drug conjugate designed to deliver a cancer-killing drug directly to tumor cells. It enrolls 117 adults with advanced solid tumors or B-cell lymphomas that have not responded to standard treatments. The main goals are to check saf…

This early-stage trial tests two experimental mRNA therapies (mRNA-4106 and mRNA-4200) in 42 people with advanced solid tumors like melanoma, lung, or liver cancer. Some participants receive the mRNA therapy alone, others get it combined with the immunotherapy drug pembrolizumab.…

This early-phase study tests an experimental drug called VAX014, which is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The study will first find a safe dose of VAX014 alone, then te…

This study tests a new combination of two drugs, AMT116 and ivosimab, in people with advanced non-small cell lung cancer that cannot be removed by surgery. The goal is to find the safest dose and see if the combination shrinks tumors. About 118 adults aged 18 to 75 will take part…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

This trial is testing whether giving a combination of oral paclitaxel (a chemotherapy pill), an immunotherapy drug, and focused radiation before surgery can help older adults with stage IIA-IIIB non-small cell lung cancer. The goal is to see if this pre-surgery treatment can shri…

This early-stage trial tests an experimental oral drug called SHY-ONC6 in people with advanced or metastatic solid tumors (including breast, colon, lung, pancreatic, and others) that have stopped responding to standard treatments. The study aims to find a safe dose and check for …

This study tests whether the drug divarasib can prevent lung cancer from coming back in people with a specific gene mutation (KRAS G12C) who have already had surgery and chemotherapy. About 400 adults with stage II-III non-small cell lung cancer will be randomly assigned to recei…

This phase 3 trial compares a new drug called pumitamig to the standard drug pembrolizumab as a first treatment for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1 (at least 50%). The study will enroll 750 participants and measure ho…

This study tests a new drug called volrustomig combined with other cancer treatments for people with advanced non-small cell lung cancer. The main goals are to check safety and see if tumors shrink. About 180 adults will take part in this early-stage trial.

This study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…

This study looks at whether non-small cell lung cancer patients who are less fit (performance status 2) can be treated just as effectively with a combination of chemotherapy and immunotherapy as those who are more fit (performance status 0-1). About 105 participants will receive …

This study tests an experimental oral drug called GS-1206 in adults with advanced or metastatic solid tumors that have a specific genetic mutation. The main goals are to evaluate the drug's safety, tolerability, and how the body processes it. Participants must have tumors that ha…

This early-stage trial is testing an experimental drug called MK-4716, alone or combined with other cancer drugs, in people with advanced solid tumors that have a KRAS mutation. The main goal is to see if the drug is safe and tolerable. About 250 participants will be enrolled.

This trial is testing a new drug called DS1025a in people with advanced solid tumors that have spread, cannot be removed by surgery, or have stopped responding to other treatments. The main goals are to check the drug's safety, how the body processes it, and whether it shows any …

This study tests whether adding radiation therapy to the usual maintenance drug atezolizumab helps people with extensive-stage small cell lung cancer live longer without their cancer growing. About 138 participants who have already responded to initial chemo-immunotherapy will be…

This study tests whether adding a new drug called navlimetostat to standard immunotherapy (pembrolizumab) and chemotherapy helps people with a specific genetic form of advanced lung cancer (MTAP deletion) live longer without their cancer worsening. About 590 participants will be …

This study tests an experimental drug called BLU-924 (SAR449336) in people with advanced pancreatic, lung, or colorectal cancers that have specific KRAS mutations. The drug is designed to block the cancer-driving KRAS protein. The trial will enroll about 265 participants to evalu…

This study tests a drug called divarasib, either alone or with other cancer treatments, in people with advanced lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if the drug is safe and works to shrink or control the cancer. About 320 people who have …

This study tests whether adding an experimental mRNA vaccine (V940) to the immunotherapy drug pembrolizumab (Keytruda) can keep lung cancer from returning after surgery. It includes 680 people with stage II to IIIB non-small cell lung cancer whose tumors did not fully respond to …

This early-stage trial tests an experimental pill called JBI-778 in people with certain advanced cancers: EGFR-mutated lung cancer (with or without brain metastases), recurrent high-grade glioma, or adenoid cystic carcinoma. The drug is designed to block a protein that helps canc…

This early-stage trial is testing an experimental drug called MBS8(1V270), given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 1…

This phase II trial tests whether adding local treatments like surgery or radiation to the immunotherapy drug durvalumab can help control stage III non-small cell lung cancer that has progressed after chemoradiation and durvalumab. About 51 participants with 3 or more growing tum…

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This phase III trial is investigating whether surgically removing the primary lung tumor, in addition to continuing the targeted therapy osimertinib, can prolong the time before disease progression in patients with EGFR-mutant non-small cell lung cancer that has spread to a limit…

This early-stage study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The main goals are to find the safest dose and check for side effects. About 193 participants will take the drug alo…

This trial is for people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer) that has spread to the lining of the brain and spinal cord (leptomeningeal metastasis) and has stopped responding to third-generation targeted pills. The study tests whether a pe…

This study tests whether using inhaled budesonide (a steroid commonly used for asthma) for one year can stop lung inflammation from coming back in cancer patients who had a serious immune reaction to immunotherapy. About 94 adults with solid tumors who recently had lung inflammat…

This study tests a new drug, setidegrasib, against a standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific KRAS G12D mutation. The goal is to see if setidegrasib can keep the cancer from growing longer and help people live longer…

This early-stage trial is testing an experimental drug called DM005 in 136 people with advanced solid tumors, including lung, head and neck, and other cancers that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and se…

This early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…

This early-phase trial is testing whether combining two experimental drugs, tarlatamab and ZL-1310, with or without the immunotherapy durvalumab, can safely shrink tumors in people with small cell lung cancer that has worsened after standard treatment. About 160 adults will take …

This trial tests several cancer drugs in children and young adults with solid tumors. It uses a master protocol to test different drug combinations more efficiently. About 105 participants will receive one of eight drugs, including ramucirumab, cyclophosphamide, and others. The g…

This Phase 3 trial tests whether adding a maintenance drug (sacituzumab tirumotecan) after initial chemo-immunotherapy improves survival in people with metastatic squamous non-small cell lung cancer. About 851 participants will receive pembrolizumab plus chemotherapy, then either…

This study tests a new drug, LY4050784, in people with advanced solid tumors that have a specific change in the SMARCA4 gene. The goal is to see if the drug is safe and works, either alone or with other cancer treatments. About 340 adults whose cancer has not responded to standar…

This trial tests whether a personalized exercise program can safely help cancer survivors improve their physical fitness and quality of life. Participants who have finished curative treatment at least two months ago will receive a tailored plan based on heart, lung, and muscle as…

This program provides early access to an experimental drug called ifinatamab deruxtecan (I-DXd) for people with extensive-stage small cell lung cancer who have already tried at least two prior treatments, including platinum-based chemotherapy. It is for patients who have no other…

This Phase 3 study tests whether adding olomorasib (a targeted pill) to standard immunotherapy (pembrolizumab or durvalumab) works better than immunotherapy alone for people with KRAS G12C-mutant non-small cell lung cancer. The trial has two parts: one for patients whose cancer w…

This trial tests whether adding the experimental drug iadademstat to standard immunotherapy (atezolizumab or durvalumab) can help keep extensive-stage small cell lung cancer from growing. About 45 adults whose cancer responded to initial chemo-immunotherapy will receive the combi…

This early-phase study tests a new drug called STRO-004 in adults with advanced solid tumors that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in more patients, and combining STRO-004 with another d…

This study tests whether taking pentoxifylline and vitamin E during chemoradiation can prevent lung injury (pneumonitis) in stage III non-small cell lung cancer patients. 150 participants will receive either the drug combo or a placebo for 6 months. The goal is to see if this red…

This early-stage trial tests a new drug called PHN-012 in people with advanced colon, pancreatic, or lung cancer that has stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a powerful cancer-killing agent directly to tumor cells…

This early-phase trial tests an experimental drug called D3S-002, taken as a daily pill, in adults with advanced solid tumors that have MAPK pathway mutations. The study has two parts: first, finding a safe dose, and second, testing that dose alone or with another drug (D3S-001) …

This trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…

This early-stage trial is testing an experimental drug called EVOLVE104 in people with advanced bladder cancer or several types of squamous cell carcinoma (lung, esophagus, skin, and others). The study aims to find a safe dose and see if the drug can shrink tumors. It is for pati…

This study follows 800 Chinese patients with early-stage ALK-positive non-small-cell lung cancer who took alectinib after surgery to see how long they stay cancer-free. Researchers will collect real-world data on disease-free survival and patient characteristics. The goal is to u…

This study tests a new targeted therapy called MK-1084, alone or combined with other drugs, in 190 people with advanced non-squamous non-small cell lung cancer that has a specific KRAS G12C mutation and has worsened after prior treatments. The main goals are to check safety and s…

This early-phase trial tests whether adding carotuximab to the standard drug osimertinib is safe for people with advanced EGFR-mutated non-small cell lung cancer. About 60 participants whose cancer has progressed on prior treatments will receive both drugs. The main goal is to fi…

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

This program offers early access to the investigational drug neladalkib for people with advanced ALK-positive lung cancer or other ALK-positive solid tumors who have run out of standard treatment options and cannot join a clinical trial. Participants must be at least 18 years old…

This study tests whether adding an experimental drug (EIK1001) to standard immunotherapy and chemotherapy helps people with stage 4 non-small cell lung cancer live longer or slow tumor growth. About 750 adults whose cancer has spread will receive either the new combination or a p…

This early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…

This early-phase trial tests a new type of cell therapy called TCR1188-ABC for people with certain advanced cancers (pancreatic, colorectal, lung, or bile duct) that have a specific KRAS G12V mutation. The treatment involves taking a patient's own immune cells, engineering them t…

This Phase 3 trial is testing a new oral drug called daraxonrasib (RMC-6236) against the standard chemotherapy docetaxel in about 590 people with advanced non-small cell lung cancer that has a specific RAS mutation. Participants must have already tried at least one prior treatmen…

This early-phase study tests a new drug called BG-C0979, alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This study tests a new drug called ifinatamab deruxtecan (I-DXd) against standard treatments for people whose small cell lung cancer has returned. About 540 adults with advanced disease will be randomly assigned to receive either I-DXd or a treatment chosen by their doctor. The g…

This trial is testing an experimental therapy called STX-003, which uses mRNA to produce a protein that may help the immune system fight cancer. It is given intravenously, either alone or with the immunotherapy drug pembrolizumab (Keytruda). The study involves adults with advance…

This early-phase trial tests the safety and best dose of two drugs—neratinib and trastuzumab deruxtecan—given together to people with advanced solid tumors that have HER2 gene changes. The goal is to see if the combination can shrink tumors that have spread or can't be removed by…

This study tests whether a new drug (divarasib) combined with immunotherapy (pembrolizumab) works better than standard chemotherapy plus immunotherapy for people with a specific genetic mutation (KRAS G12C) in advanced non-small cell lung cancer. About 600 adults who have not had…

This study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…

This early-phase study tests a new treatment called GC203 TIL, which uses a patient's own immune cells that are modified in a lab to better fight cancer. It is for adults with advanced solid tumors that no longer respond to standard therapies. The main goal is to check safety, an…

This early-stage study tests a new drug called HWK-007 in people with advanced solid tumors, including certain ovarian, endometrial, and lung cancers. The drug is designed to target a protein (PTK7) found on cancer cells and deliver a chemotherapy-like payload directly to them. T…

This trial tests an experimental drug called KLS-1, a form of zinc aspartate enriched with a specific zinc isotope, in adults with certain solid tumors (like melanoma, prostate, or pancreatic cancer) or chronic lymphocytic leukemia (CLL). The goal is to find the safest and most e…

This study tests whether adding a precise type of radiation therapy (I²-PORT) after lung cancer surgery can help prevent the cancer from coming back. Participants have non-small cell lung cancer with remaining cancer in lymph nodes after initial treatment. The trial compares stan…

This study tests a drug called adagrasib, alone or with pembrolizumab (an immunotherapy), in people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if the combination shrinks tumors and helps people live longer without t…

This phase 2 trial tests whether giving chemotherapy plus the immunotherapy drug cemiplimab (Libtayo) before surgery can shrink tumors enough to allow surgical removal in people with stage 3 non-small cell lung cancer that has spread to certain lymph nodes (N3). About 21 particip…

This study tests two experimental drugs, BNT326 and BNT327, in people with advanced non-small cell lung cancer that has spread or come back. The trial has three parts to find the best dose and check safety, and will compare the combination to standard treatments like pembrolizuma…

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

This study tests whether text-based support can help rural cancer survivors who smoke to quit. Participants will either receive text messages that gradually reduce cigarette use or a self-help manual. The goal is to see which approach works better for long-term smoking cessation.

This study tests a new drug, BH-30643, in adults with advanced non-small cell lung cancer that has certain gene changes (EGFR or HER2 mutations). The goal is to find a safe dose and see if the drug can shrink tumors. About 266 people will take part across multiple locations.

This phase II trial tests whether adding two types of precisely targeted radiation (BgRT and SBRT) to the standard drug osimertinib can better control advanced EGFR-positive lung cancer that has started to grow in a few new spots. About 32 adults with this specific type of lung c…

This early-stage trial is testing an experimental immunotherapy called AB122, given alone or combined with other investigational drugs, in people with advanced solid tumors such as pancreatic, colorectal, lung, and stomach cancers. The goal is to find out which combinations are s…

This phase II trial tests a new treatment for non-small cell lung cancer using immune cells taken from the patient's own tumor. The cells are grown in a lab and then infused back to attack the cancer. The study will enroll 28 adults and measure how well the treatment shrinks tumo…

This early-stage trial tests a personalized treatment called GC101 TIL for people with advanced non-small cell lung cancer that has not responded to standard treatments. The therapy uses immune cells taken from the patient's own tumor, multiplied in a lab, and then infused back i…

This trial investigates whether tumor-infiltrating lymphocytes (TILs) — immune cells taken from a patient's own tumor — can be expanded in the lab and infused back to attack cancer. It enrolls adults aged 18 to 75 with advanced solid tumors who have failed standard treatments. Th…

This early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…

This trial asks whether giving sintilimab, an immune checkpoint inhibitor, after complete surgical removal of non-small cell lung cancer can improve outcomes for patients at high risk of recurrence. Participants who already received chemotherapy plus an immune checkpoint inhibito…

This phase III trial is testing whether giving chemotherapy and immunotherapy both before and after surgery (perioperative) is better than giving it only after surgery (adjuvant) for people with stage II-IIIB non-small cell lung cancer that can be removed. About 1,100 participant…

This Phase 1 trial tests IDOV-Immune, a genetically engineered virus designed to infect and destroy cancer cells while boosting the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatme…

This study tests a new drug called ASP3082 in 60 people with advanced lung or pancreatic cancer that has a specific gene change (KRAS G12D). Participants receive the drug intravenously once a week in 21-day cycles. The main goal is to see how well the drug shrinks tumors and to u…

This phase II trial is testing the drug osimertinib in 46 people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). The goal is to see if the drug can shrink tumors or slow the cancer's growth. Participants will take osimertinib …

This study tests a new drug, Rina-S, in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to see if Rina-S is safe and how well it works against cancers like ovarian, lung, and breast cancer. About 884 participants will receive the dru…

This study tests the drug cabozantinib in people with advanced non-small cell lung cancer whose tumors have certain gene changes (RET, ROS1, NTRK fusions or increased MET/AXL activity). The drug is taken by mouth and aims to shrink tumors and stop them from growing. About 86 part…

This study tests a new drug, BI 1703880, combined with ezabenlimab in adults with advanced solid tumors that haven't responded to other treatments. The main goal is to find a safe dose of BI 1703880. Participants receive both drugs as infusions, with BI 1703880 given weekly then …

This study tests a new drug called Rina-S in about 240 people with advanced non-small cell lung cancer. The goal is to see if the drug can shrink tumors or slow cancer growth. All participants receive the active drug, and treatment may continue as long as it helps and side effect…

This early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…

This study looks at whether the immunotherapy drug durvalumab can help people with limited-stage small-cell lung cancer when given after chemoradiation. Researchers will track 200 patients in China to see how long the cancer stays under control and how safe the treatment is. The …

This trial is testing a new type of cell therapy for adults with small cell lung cancer that has returned or not responded to standard treatments. The therapy uses immune cells called natural killer (NK) cells, engineered to recognize and attack cancer cells through two targets a…

This phase 3 trial tests TAK-928, a drug designed to activate T cells inside tumors, against standard chemotherapy (docetaxel) in 600 adults with advanced non-small cell lung cancer that has worsened after prior treatments. The goal is to see if TAK-928 can shrink tumors or help …

This study tests a new targeted drug called zongertinib, which blocks the HER2 protein that fuels cancer growth, in combination with standard chemotherapy (with or without the immunotherapy pembrolizumab). It is for people with advanced or metastatic non-squamous non-small cell l…

This trial is testing whether a pill form of the chemotherapy drug paclitaxel, taken alongside an immune checkpoint inhibitor, can help people with advanced lung cancer stay stable longer after their first round of treatment. The study includes two groups: one with squamous non-s…

This study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior treatment. Participants take one of two daily doses and continue as long as they benefit. Doctors regularly check tumor…

This early-stage trial tests a new drug called EVM14, given alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have spread or come back. The main goals are to check safety, find the right dose, and see if the drug helps control the cancer. A…

This early-phase study tests whether adding an experimental drug (DSP-0390) to the immunotherapy atezolizumab can safely help prevent extensive stage small cell lung cancer from growing back after initial chemotherapy and immunotherapy. About 20 adults whose cancer did not worsen…

This early-stage study tests a new drug called XmAb819 in people with advanced clear cell kidney cancer that has come back or not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 307 participants will receive the drug int…

This study tests a new drug, firmonertinib, against two standard treatments for people with advanced non-small-cell lung cancer that has certain rare genetic changes (EGFR PACC mutations). About 480 participants who have not had prior treatment for advanced disease will be random…

This study is testing whether giving lower, less frequent doses of the cancer drug atezolizumab can still keep enough drug in the blood to fight cancer. About 30 adults with certain advanced cancers (like lung cancer or melanoma) will start with standard doses, then switch to a l…

This study tests whether adding a new drug called BL-B01D1 to the standard targeted therapy osimertinib can improve outcomes for people with a specific type of lung cancer (EGFR-mutated non-small cell lung cancer) that can be removed with surgery. About 90 participants will recei…

This phase 2 trial is testing whether adding a targeted therapy called fumetinib to chemotherapy before standard chemoradiation can improve outcomes for people with stage III non-small cell lung cancer that has EGFR mutations and cannot be removed by surgery. Participants are ran…

This early-phase study tests a new drug (PLN-101095) alone or with pembrolizumab in adults whose advanced solid tumors have stopped responding to standard immunotherapy. About 124 participants will receive the treatment to check safety and early signs of tumor shrinkage. The goal…

This early-phase trial is testing a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in people with solid tumors. The vaccine is custom-made for each patient to target their specific cancer. The study aims to check the safety of this combina…

This trial tests whether a short course of exercise before lung cancer surgery can improve patients' fitness and post-operative outcomes. Participants with moderate-to-high surgical risk will be randomly assigned to either moderate-intensity continuous training or high-intensity …

This study tests two experimental drugs, elironrasib and daraxonrasib, given alone or together, in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drugs are safe and can shrink or control the cancer. About 534 adults with lung,…

This phase 3 study compares a new biologic drug, rilvegostomig, to the standard drug pembrolizumab (Keytruda) as a first treatment for people with advanced non-small cell lung cancer that has high PD-L1 levels. About 830 participants worldwide will receive either drug by IV every…

This early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…

This early-stage study tests a new drug called MK-4884 in about 120 people with advanced or metastatic solid tumors (colorectal, kidney, lung, or bile duct cancer). The main goal is to check the drug's safety and find the right dose. Researchers will monitor side effects and how …

This study tests whether combining experimental RAS(ON) inhibitors with ivonescimab (an immunotherapy) can shrink or control advanced solid tumors that have a RAS mutation. About 370 adults with cancers like non-small cell lung cancer or colorectal cancer will receive these drugs…

This study tests a new drug called LM-168 combined with other cancer treatments (tislelizumab or docetaxel) in 108 adults with advanced solid tumors. The first part finds a safe dose; the second part checks if the combination shrinks tumors. It is not yet recruiting.

This trial is testing an experimental drug called petosemtamab (MCLA-158) in people with advanced solid tumors, including colorectal, head and neck, and lung cancers. The drug is a bispecific antibody designed to block two cancer-related proteins, EGFR and LGR5. Researchers want …

This early-phase trial is testing an experimental drug called ROSE12, alone or combined with other anti-tumor agents, in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to evaluate safety, determine the best dose, and look…

This early-stage trial is testing a new type of radiation therapy that seeks out and attacks cancer cells while sparing healthy tissue. It's for people with advanced breast, lung, stomach, or bladder cancer who have run out of standard options. The study will check if the treatme…

This phase 3 trial is testing whether adding one or two immune-boosting antibodies—toripalimab alone or combined with tifcemalimab—after standard chemoradiotherapy can help people with limited-stage small cell lung cancer live longer without the cancer growing. About 756 particip…

This phase 3 trial is testing an experimental drug called VC004 in people aged 12 and older with advanced or metastatic solid tumors that cannot be removed by surgery. The goal is to see whether VC004 capsules can shrink tumors and control the disease. All participants receive th…

This large trial tests whether a structured program called RESET can improve outcomes for adults undergoing planned cancer surgery. RESET combines pre-surgery preparation (prehabilitation), enhanced in-hospital recovery practices, and personalized support after discharge. Researc…

This early-stage trial is testing an experimental oral drug called ISM8207 in people with advanced solid tumors or relapsed/refractory B-cell lymphoma who have no standard treatment options left. The main goals are to check the drug's safety, tolerability, and how the body proces…

This phase 2 trial tests whether adding two experimental drugs, imzokitug and pumitamig, to standard chemotherapy helps people with advanced non-small cell lung cancer (NSCLC) who have not had prior treatment. About 160 participants will receive either the three-drug combination …

This early-phase trial is testing an experimental drug called M3T01, a monoclonal antibody that targets a protein called FasL, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study aims to see if M3T01 is safe and tolerable when given al…

This trial is testing an experimental drug called AT-1965 in people with advanced solid tumors that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and then seeing whether the drug can shrink tumors. About 100 participants will…

This trial is testing an experimental drug called BL-M07D1 in people with a specific type of advanced non-small cell lung cancer that has a HER2 mutation. The study aims to find the best dose and see how well the drug shrinks tumors, while also checking for side effects. Particip…

This early-phase trial is testing an experimental biologic drug, DBC-664, in adults with advanced solid tumors such as ovarian, lung, and stomach cancers that have spread or come back. The study has two parts: first, finding a safe dose, and then expanding to see how well the dru…

This early-phase trial is testing an experimental oral drug called APG-2449 in people with advanced solid tumors, including certain lung cancers, mesothelioma, esophageal cancer, and ovarian cancer. APG-2449 is designed to block several proteins (FAK, ALK, and ROS1) that help can…

This trial tests whether a type of minimally invasive lung surgery that avoids inserting a breathing tube (non-intubated thoracoscopic surgery) can reduce complications in patients with impaired lung function. These patients often need ICU care after standard surgery because thei…

This phase II trial is testing whether combining an experimental drug called BL-B01D1 with a PD-1 monoclonal antibody can shrink tumors in people with extensive-stage small cell lung cancer. The study enrolls 66 adults aged 18 to 75 who have newly diagnosed, advanced disease. Res…

This early-stage trial tests an experimental oral drug called APG-2449, alone or combined with another cancer drug, in people with platinum-resistant recurrent ovarian cancer or other advanced solid tumors. The study aims to find safe doses and understand how the drug works in th…

This trial tests whether combining two drugs—dupilumab and cemiplimab—given before surgery can improve outcomes for people with early-stage non-small cell lung cancer. Participants receive one dose of each drug, then undergo standard surgery about two weeks later. Researchers mon…

This study tests whether digital tools—text messages, a chatbot, an educational video, and patient navigation—can help more people in low-resource clinics get screened for lung cancer. Participants are current or former smokers aged 50–80 who speak English or Spanish and have a p…

This study compares two different schedules of stereotactic body radiotherapy (SBRT) for people with early-stage non-small-cell lung cancer. Patients are randomly assigned to receive radiation over 3 days or 5 days. The main goal is to see if one schedule causes fewer severe side…

This study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…

This trial tests SPEDOX-6, a version of the chemotherapy drug doxorubicin wrapped in a protein shell, in people with advanced solid tumors such as soft-tissue sarcoma, triple-negative breast cancer, non-small cell lung cancer, cervical cancer, ovarian cancer, and certain pancreat…

This phase 1 trial tests an experimental drug called ACM-CpG, given as a shot into the muscle, in people with advanced solid tumors that have not responded to standard immunotherapy. The drug is designed to activate the immune system to attack tumors. The study aims to find the s…

This phase 1 trial tests an experimental drug called PA5 in adults with advanced solid tumors that have not responded to standard treatments. PA5 is designed to break down arginine, an amino acid some cancers need to grow. The study aims to find the safest dose and check for side…

This study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B…

This phase 2 trial tests a new drug called AK146D1, given together with other cancer drugs, in 348 people with advanced non-small cell lung cancer that cannot be surgically removed. The study aims to see if the combination is safe and can shrink tumors. Participants will receive …

This early-phase trial tests a new combination treatment for people with a specific type of advanced lung cancer (non-small cell lung cancer) that has spread and shows a marker called FAP on scans. The treatment pairs a targeted radiation drug (177Lu-RTX-2358) with a standard imm…

This study tests an experimental therapy called YH02, a genetically modified virus designed to infect and destroy cancer cells. It is given as an injection directly into tumors in people with advanced solid tumors (such as head and neck cancer, breast cancer, or melanoma) that ha…

This study tests an experimental oral drug called VRN110755 in people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer). The drug is designed to block cancer growth by targeting the EGFR protein and certain resistance mutations, including C797S. The tri…

This study looks at how well the immunotherapy drug ivonescimab works when used alone as the first treatment for people with advanced non-small cell lung cancer that has a specific marker (PD-L1 positive) and no targetable gene mutations. About 265 participants will receive ivone…

This study tests a program where clinical pharmacists provide personalized counseling to cancer patients taking oral anticancer drugs. The goal is to see if this support helps patients take their medication more consistently. Researchers will compare two groups of 80 patients eac…

This trial looks at whether surgically removing the primary lung tumor can help people with M1a stage lung cancer, where cancer cells are found in the chest lining during surgery. The study includes 66 adults aged 18–80 who have not had prior lung cancer treatment. Researchers wi…

This study tests whether adding focused radiation or ablation to standard drug therapy can help people with lung cancer that has only a few new spots of growth. The goal is to see if this approach allows patients to stay on their current treatment longer without needing to switch…

This study tests a three-part program to increase the use of precision oncology—genetic testing that guides personalized treatment—for veterans with advanced lung or prostate cancer. The program includes a patient education video, feedback to doctors on their testing patterns, an…

This phase 2 trial tests a combination of two drugs—lucankizumab and goleirex—as a first treatment for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The study will enroll 43 participants to see if the combo shrinks tumors and how safe it …

This study tests a new drug called HS-20122 in combination with other cancer medicines for people with advanced non-small cell lung cancer. The trial includes three different drug combinations depending on the patient's tumor type. The main goals are to check safety, find the bes…

This phase 1 trial tests a new drug called AWT020, given alone or with other cancer treatments, in people with advanced solid tumors such as non-small cell lung cancer, colorectal cancer, kidney cancer, and melanoma. The main goals are to check the drug's safety, find the best do…

This trial compares oral nicotine pouches (like ZYN) with standard nicotine replacement therapy (patches and lozenges) to help smokers in rural Appalachia reduce or stop cigarette use. The goal is to lower the high rates of lung and oral cancers linked to smoking in this region. …

This trial investigates whether adding papaverine—a drug traditionally used as a muscle relaxant—to standard chemoradiation can improve treatment for people with stage II to III non-small cell lung cancer. Papaverine targets the energy factories inside cancer cells (mitochondria)…

This study tests a new drug called HRS-4508 in combination with other cancer treatments (such as capecitabine, trastuzumab, and pertuzumab) for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find the best dose, check safety, and…

This Phase 2 trial is testing a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in low, frequent doses to people with advanced solid tumors that have not responded to prior treatments. The goal is to see if this approach can slow tumor growth and improv…

This study tests a new device that uses microwave energy to destroy lung tumors during a bronchoscopy, before the patient has surgery to remove the tumor. The goal is to see if the device is safe and works well in 30 people with confirmed lung cancer who are already scheduled for…

This phase 2 trial tests whether adding tafolecimab (a cholesterol-lowering drug) to standard chemotherapy and the immunotherapy sintilimab helps people with extensive-stage small cell lung cancer live longer without their cancer growing. About 40 adults who have not had prior tr…

This study tests whether a new drug called SCTB41, when combined with chemotherapy, works better than the standard immunotherapy tislelizumab plus chemotherapy for people with advanced non-small cell lung cancer that has no targetable genetic mutations. The trial has two parts: a…

This trial investigates whether specially engineered T cells can safely target and fight lung cancer. Participants have advanced or relapsed lung cancer and receive a single infusion of their own T cells that have been trained to recognize cancer-specific markers. The study aims …

This study tests a new treatment called 4SCAR-276 for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that have a protein called CD276. The tria…

This phase 3 trial tests whether a combination of an injected virus therapy (CAN-2409) and an immunotherapy drug (pembrolizumab) can help people with stage IV non-squamous non-small cell lung cancer live longer than standard chemotherapy. The virus is designed to kill tumor cells…

This phase 1 trial tests an experimental drug, DXC006, in people with advanced solid tumors (like small cell lung cancer and neuroblastoma) or blood cancers (like multiple myeloma) who have not responded to standard treatments. DXC006 is an antibody-drug conjugate designed to del…

This trial investigates whether combining two targeted drugs, vebreltinib and furmonertinib, can control advanced non-small cell lung cancer in people whose tumors have both an EGFR mutation and high PD-L1 expression. The study enrolls about 45 adults who have not received prior …

This study tests a lower-dose radiation regimen for people with non-small cell lung cancer located near the center of the chest. The goal is to see if giving a total of 45 Gray in three sessions can control the tumor while reducing damage to nearby organs like the heart and major…

This phase 1 trial tests whether specially designed viruses (VSV-based oncolytic viruses) can safely treat advanced solid tumors that have not responded to standard treatments. The viruses are injected into the body to infect and destroy cancer cells. The study focuses on safety …

This phase 2 trial is testing whether adding two immunotherapy drugs, IPH5201 and durvalumab, to standard chemotherapy before and after surgery can improve outcomes for people with early-stage (stage II to III) non-small cell lung cancer. The study includes two groups: one receiv…

This study investigates whether a lower dose of two chemotherapy drugs (carboplatin and nab-paclitaxel) combined with a delayed dose of the immunotherapy serplulimab can effectively treat advanced squamous non-small cell lung cancer. The trial compares this gentler regimen to a s…

This phase 2 trial tests a new radiation technique called SBRT-LATTICE-PATHY for people with large tumors (at least 7 cm or 340 cm³) that cannot be treated with standard methods. The approach delivers a high dose of radiation only to low-oxygen areas inside the tumor, aiming to i…

This study tests an experimental drug called RMC-9805, taken as a pill, in adults with advanced solid tumors (such as lung, colorectal, or pancreatic cancer) that have a specific mutation in the KRAS gene called G12D. The drug is given alone or in combination with another oral dr…

This study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…

This early-phase trial tests whether a PET/CT scan using an investigational tracer called zirconium Zr 89 crefmirlimab berdoxam can safely and effectively spot CD8+ T cells—key immune cells that attack cancer—in people with metastatic non-small cell lung cancer. Participants are …

This trial is testing whether advanced PET-CT scans can spot early signs of heart damage caused by standard radiation therapy for locally advanced non-small cell lung cancer. Ten adults with stage III lung cancer will receive a special PET-CT scan before and three months after th…

This trial is testing whether a new radioactive tracer, called 68Ga-SorB, can help doctors see certain solid tumors on PET/CT scans. The tracer targets sortilin, a protein that is often found on cancer cells. About 50 adults with melanoma, liver, lung, breast, pancreatic, or ovar…

This study tests a new radioactive tracer called 89Zr-DFO-SC16.56 that attaches to a protein called DLL3 found on small cell lung cancer cells. The goal is to see if PET scans using this tracer can safely and accurately show where the cancer is in the body. About 53 adults with s…

This trial is testing whether a new PET imaging agent can safely and effectively detect a protein called MMP14 on solid tumors. The study will involve about 30 adults with various solid tumors, such as melanoma, lung, or breast cancer. Each participant will receive the experiment…

This study is testing a new device called a nitride-based Raman biochip that analyzes blood samples using light to detect molecular patterns linked to lung cancer. Researchers will compare results from 2,000 people with lung cancer and 1,000 without to see if the test can accurat…

This trial is testing whether a radiolabelled version of the drug patritumab deruxtecan (HER3-DXd) can be used as a PET imaging tracer to visualize HER3 protein throughout the body in people with advanced EGFR-mutant non-small cell lung cancer. The goal is to find the best imagin…

This study is testing a lung cancer screening program for smokers aged 45 to 74. It uses low-dose CT scans and metabolomics to find lung nodules and reduce false negatives. The goal is to improve early detection and help smokers quit. 1,000 participants will be followed in a publ…

This study evaluates a rapid test called Methylscape that measures DNA methylation patterns in body fluids like blood, urine, or saliva. The goal is to see if it can detect a cancer signal and even predict where the cancer started, using a single sample. Researchers will compare …

This trial is investigating whether a new radioactive tracer called 18F-grazy-02, used with PET/CT scans, can safely and effectively monitor how well immunotherapy is working in people with lymphoma or solid tumors. The tracer targets granzyme B, a protein released by immune cell…

This trial tests an artificial intelligence platform called NodeAI that analyzes ultrasound images in real time during a lung cancer staging procedure. The goal is to see if the AI can predict whether lymph nodes contain cancer more accurately than a surgeon's visual assessment. …

This study is testing whether a blood test that looks for specific chemical changes on DNA can help diagnose lung cancer. Researchers will collect blood samples from 750 adults, including those with lung cancer, precancerous conditions, and healthy volunteers, and analyze the DNA…

This phase 1 trial is testing whether a new imaging tracer called 18F-TRX can safely and effectively detect solid tumors using PET scans. The tracer targets unstable iron levels, which are often elevated in cancerous tissue. Adults with advanced solid tumors, including certain pr…

This study is testing whether a blood test that looks for bits of tumor DNA (called ctDNA) can predict how well people with early-stage lung cancer respond to treatment. Researchers want to see if the test can identify patients who have no cancer left after chemotherapy and immun…

This study explores whether a biosensor using trained laboratory animals can detect non-small cell lung cancer (NSCLC) by smelling unique chemicals in urine. Participants include people with and without NSCLC, as well as those suspected of having it. The goal is to see if this an…

This study tests a new imaging agent called F18 FBPA, which is designed to light up cancer cells during a PET/CT scan. The agent targets a protein often found on solid tumors, potentially making tumors easier to see. Researchers want to find the best dose and timing for the scan,…

This study tests whether a special lung MRI, combined with a computer-generated CT-like image, can accurately detect lung cancer in heavy smokers. Participants are 55–74 years old with a solid lung nodule found on a prior scan. The goal is to see if this non-invasive method can r…

This study tests a new total-body PET scanner called the Biograph Vision Quadra to see if it can produce clearer images and find more tumors than standard PET/CT scanners. The study includes adults with non-small cell lung cancer, head and neck cancer, or prostate cancer who are …

This trial investigates whether a femtosecond laser combined with an artificial intelligence model can diagnose lung cancer from fresh tissue samples as accurately as the standard frozen section method. About 294 adults scheduled for lung surgery will have their tumor specimens e…

This study tests a new type of PET/CT scan that looks for a protein called DLL3 on small cell lung cancer cells. The goal is to see if this scan can find tumors more clearly than standard imaging methods like CT or regular PET scans. About 20 adults with suspected or confirmed sm…

This trial tests whether a mobile app called Wellnuts can help healthy adults aged 25–65 in Hong Kong become more aware of their health risks and take action. Participants use the app to assess their risk for conditions like diabetes, heart disease, and certain cancers, and recei…

This trial tests whether adding acupoint application—a herbal plaster placed on specific body points—to a standard anti-nausea drug can better control nausea and vomiting caused by chemotherapy in adults with lung cancer. Participants receiving first-line platinum-based chemother…

This study observes about 700 people with lung or liver cancer who are already receiving atezolizumab as a shot under the skin. Researchers want to see how satisfied patients are with this treatment and how it affects their quality of life. The study does not test a new drug but …

This study explores whether a brief behavioral program can help cancer patients and their sleep partners get better rest. The program teaches techniques like limiting time in bed and going to bed only when sleepy, aiming to improve sleep efficiency. Participants, who are couples …

This phase II trial tests whether esomeprazole, a common acid-reducing drug, can lower the chance of severe esophagitis (inflammation of the food pipe) in people with stage III non-small cell lung cancer receiving radiation therapy. Participants take 40 mg of esomeprazole daily d…

This study tests whether acupressure can reduce coughing and related symptoms like shortness of breath and fatigue in lung cancer survivors. Eighty participants will either perform acupressure for 8 weeks or receive an educational booklet. Researchers will track changes in cough …

This study tests whether a CPAP device can reduce tumor movement in lung cancer patients during stereotactic body radiation therapy (SBRT). About 30 participants will use CPAP or deep inspiration breath hold to see which better stabilizes tumors. The goal is to improve treatment …

This study looks at whether 12 weeks of different exercise programs can help people with advanced lung cancer who are already receiving immunotherapy. The goal is to see if exercise is safe and doable, and if it can improve immune markers. About 30 adults with non-small cell lung…

This trial tests whether a newer ultrasound-guided nerve block, called retro-SCTLB, provides better pain relief after minimally invasive lung cancer surgery than the standard thoracic paravertebral block. Adults aged 18-80 scheduled for thoracoscopic lung cancer removal will be r…

This pilot study tests whether a personalized exercise program is practical for 20 adults with stage II or III non-small cell lung cancer who are about to start treatment. Participants will follow the Precise Exercise Regimen for Cancer Care (PERCC) program before and after their…

This trial tests whether changing how the arms are positioned during lung surgery can prevent shoulder pain on the operated side. Shoulder pain is common after thoracoscopic lobectomy, affecting up to 58% of patients, and can hinder recovery. The study will enroll 270 adults sche…

This study tests if a steroid mouthwash can prevent or reduce mouth sores caused by the cancer drug datopotamab deruxtecan (Dato-DXd). About 100 adults with advanced breast or lung cancer will use the mouthwash and be monitored for 12 weeks. The goal is to see if this simple step…

This study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…

This study tests whether psilocybin, the active ingredient in magic mushrooms, can help relieve severe pain in people with advanced cancer when opioids don't work. Fifteen participants will receive psilocybin capsules along with therapy sessions. The goal is to see if this approa…

This study is testing a stress management program designed for people with lung cancer who are waiting for routine scan results. The program includes a short orientation, self-guided web modules with stress management exercises, and coaching calls. Researchers want to see if the …

This study tests whether a therapy called Meaning-Centered Psychotherapy for Latinos (MCP-L) can help reduce anxiety and depression in 300 Latino patients with advanced cancer. Participants receive either MCP-L or standard cognitive behavioral therapy over about 3 months. The goa…

This study tests a navigation program for cancer patients starting immunotherapy. The program helps with essential needs like food, transportation, and housing, and tracks side effects. Researchers want to see if this support helps patients continue their treatment and improves t…

This trial tests whether Yunzhi essence, a mushroom extract from Coriolus versicolor, can improve quality of life for people with advanced cancer. Participants take either the extract or a placebo for six months, while researchers measure changes in well-being, survival, and immu…

This study tests a nurse-led support model (ICSM) for family caregivers of older adults newly diagnosed with advanced non-small cell lung cancer. The program includes education, counseling, symptom management, and a web-based resource platform. Researchers will measure whether it…

This study tests whether a homeopathic product called Encer can reduce fatigue in people with solid tumors who are starting chemotherapy or radiation therapy. Participants are randomly assigned to receive either Encer or a placebo, and their fatigue levels are tracked using a que…

This study tests whether special hairstyling methods — like braids, cornrows, or a conditioner-and-water mix — can help scalp cooling caps work better to prevent hair loss during chemotherapy. It focuses on people with curly or kinky hair (types 3 and 4), who have been underrepre…

This study tests whether riluzole, a drug already used for ALS, can help cancer survivors who struggle with memory, focus, and mental clarity after treatment — a condition called cancer-related cognitive impairment. Researchers will measure changes in a brain protein called BDNF …

This study tests a new program called Open Door for Cancer (OD-C) designed to help older adults (65+) who have been diagnosed with breast, colorectal, lung, or prostate cancer and are feeling depressed. The program aims to make it easier for them to start mental health care. Rese…

This study tests whether a mobile app called THRIVE can help people with newly diagnosed advanced lung cancer feel better day-to-day. Researchers will compare quality of life, physical and emotional symptoms, and coping skills between app users and those receiving usual care. The…

This phase 2 trial tests whether a combination of olanzapine and ondansetron can prevent nausea and vomiting caused by high-dose cisplatin chemotherapy in people with solid tumors. The approach aims to reduce steroid use by omitting dexamethasone on days 2 through 4. The study en…

This trial investigates whether a comprehensive geriatric assessment—a detailed evaluation of an older person's health, function, and social support—can help doctors make better treatment decisions for adults aged 60 and older with non-small cell lung cancer. Participants receive…

This trial tests whether giving the painkiller parecoxib before a CT-guided wire placement can reduce pain during lung nodule localization for surgery. About 150 adults with lung cancer scheduled for video-assisted thoracoscopic surgery will receive either parecoxib or a placebo …

This trial investigates whether an online, nurse-guided version of cognitive behavioral therapy (CBT) can reduce severe fatigue in people with advanced cancer who are receiving palliative systemic treatment. Participants complete a 12-week online CBT program with support from the…

This study is building a large collection of blood, saliva, urine, stool, and tissue samples from people who are at increased risk of cancer, including those with genetic predispositions, survivors of childhood or adult cancer, or those with precancerous conditions. The goal is t…

This study is a disease registry that will follow about 700 people with advanced non-small cell lung cancer that has a specific genetic change called METex14 skipping. Researchers will collect information on patient characteristics, treatments, and outcomes over time to better un…

This study collects blood or cheek swab samples from 1,100 cancer patients at the National Cancer Institute to analyze genetic differences that may influence how their bodies process cancer treatments. The goal is to understand why some patients experience more side effects or le…

This study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancers behave and why some respond differently to treatments. Participants provide samples over time and …

This study interviews 40 young adults aged 18-30 who use both tobacco (cigarettes or vaping) and cannabis at least weekly. Researchers want to learn how and why people start, increase, and keep using both substances together. The goal is to better understand these behaviors, not …

This study looks at factors that might increase the risk of lung cancer in women aged 40 to 74 who have never smoked. Researchers will collect questionnaires and blood samples from 500 women—some with lung cancer and some without—to analyze genetic and exposure-related clues. The…

This observational study will follow about 2,000 patients in China who have early-stage lung cancer with a specific gene mutation (EGFR) and have received targeted therapy pills (EGFR-TKIs) after surgery. Researchers will track how long patients live and how long they stay cancer…

This study looks at the best times to send messages that encourage physical activity to older cancer survivors (65+) who have chronic pain. About 50 participants will wear an activity tracker and rate their pain four times a day using a smartphone app. The goal is to see if certa…

This study collects blood and other biospecimens from adults with cancer to analyze immune-suppressing cells and genetic changes. Up to 1,750 participants will provide samples before and after chemotherapy. The goal is to better understand how cancer affects the immune system, bu…

This study looks at whether getting immunotherapy in the morning or afternoon changes how well it works for people with stage II-III lung cancer before surgery. About 156 participants will receive standard treatment plus immunotherapy at different times of day. The goal is to see…

This early-phase trial will test a new PET imaging agent called 64Cu-DOTA-pembrolizumab in 6 people with stage IV non-small cell lung cancer who are already on the immunotherapy drug pembrolizumab. The goal is to see if the imaging agent can safely tell the difference between tum…

This study looks at whether a campaign called Pink & Pearl can increase lung cancer screening among women who are already getting mammograms. Researchers will track how many eligible women get screened and what factors help or hinder the process. About 279 women aged 50-80 with a…

This study is creating a decision aid called TA-DA to help people with advanced cancer talk with their doctors about whether to try more treatments after several have already failed. The tool is designed to support shared decision-making. Researchers will test it with 155 patient…

This study analyzes tumor tissue from 797 people with relapsed small cell lung cancer to identify genetic subtypes. No drugs are tested here. Instead, the results may help match patients to future targeted therapy trials. Participants must have had prior platinum-based chemothera…

This early-phase study is looking at how a new drug called rezatapopt affects the way the body processes four common medications (metformin, rosuvastatin, repaglinide, and midazolam) in people with advanced solid tumors that have a specific genetic mutation (TP53 Y220C). The goal…

This study explores whether analyzing the genetic makeup of a tumor biopsy can help identify advanced cancer patients who might benefit from targeted treatments. Adults with solid tumors who have no standard treatment options will have a biopsy of their lesion for molecular profi…

This observational study is following about 2,400 adults with non-small cell lung cancer or breast cancer to see how biomarkers, including whole-genome sequencing, relate to their outcomes. Participants receive their usual cancer care, and researchers track progression-free survi…

This study looks at medical records of 3000 people in China with early-stage non-small cell lung cancer (stages I to III). The goal is to understand what treatments patients receive, how often biomarker testing is done, and what happens to them over time. No new treatments are gi…

This study tests a decision-making support program based on restorative justice principles, designed specifically for Black adults who are at high risk for lung cancer. The goal is to see if this approach increases understanding, trust, and willingness to get screened. Forty-five…

This study looks at whether a campaign called Pink & Pearl can help more women get screened for lung cancer. About 5,500 women aged 50-80 who get mammograms at Christian Hospital will take part. Researchers will track how many complete lung cancer screening and how long it takes,…

This study looks at whether genetic markers in tumor tissue, blood, and stool can predict how well lung cancer patients respond to immunotherapy. Researchers will analyze samples from 2,000 adults with lung cancer who are receiving immune checkpoint inhibitors, searching for patt…

This study looks at tumor samples from 2,100 Chinese patients with lung, gynecologic, bile duct, or bladder cancers. Researchers will compare different HER2 testing methods to see how well they agree with each other. The goal is to improve the accuracy of HER2 testing, which help…

This study tracks 150 people with non-small cell lung cancer who are getting chemotherapy and radiation followed by immunotherapy. Researchers collect blood, saliva, stool, and lung fluid samples, along with regular lung function tests, to find early signs of lung inflammation (p…

This study is collecting information from 650 people with advanced lung cancer to create 'control arms' — groups that help researchers compare how well new treatments work. Participants will receive standard therapies, and their outcomes will be tracked. The goal is to make futur…

This study looks at how the cancer drug pralsetinib (Gavreto) affects the way the body breaks down other drugs and hormones. Researchers will give a cocktail of common medications and a hormone-based contraceptive to people with advanced solid tumors, then measure how pralsetinib…

This study aims to understand cancer-related fatigue in people with non-small cell lung cancer who are receiving immunotherapy. Researchers will interview 20 patients about their fatigue, daily function, and views on physical activity. The goal is to learn how fatigue affects pat…

This study screens adults with certain cancers (like melanoma, lung, or colorectal cancer) to see if they qualify for experimental treatments being tested by the NCI Surgery Branch. These treatments involve taking a patient's own immune cells, growing them in a lab, and giving th…

This study collects tissue samples and health information from 2000 adults with certain lung and thymic cancers. Researchers aim to better understand these diseases, which could lead to new diagnostic tools and treatments. Participants provide blood, tumor samples, and imaging da…

This study is a registry that will follow 600 people with early-stage lung cancer who undergo a surgery called segmentectomy. Participants will fill out questionnaires about their health before surgery, shortly after, and six months later. The goal is to measure how long people l…

This study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …

This study aims to collect blood, urine, tumor samples, and health data from up to 1,000 people with malignant mesothelioma or other cancers that express a protein called mesothelin. Participants will be followed over time to track the course of their disease. The goal is to buil…

This study looks at how PET/CT scans change during chemoimmunotherapy and radiation for stage IV non-small cell lung cancer. Researchers want to see if these scans can help predict how well the cancer responds to treatment. About 80 participants will undergo standard treatment al…

This study collects blood, tumor, and other tissue samples from up to 1,250 people with head and neck, lung, or gastrointestinal cancers. Researchers want to understand how the immune system changes during cancer treatments, especially immunotherapies. Participants donate samples…

This study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…

This study collects extra blood, urine, and tumor samples from children and adults with certain cancers to build a large tissue repository. Researchers will analyze these samples to learn more about the genetic and molecular makeup of these tumors. The goal is to support future s…

This study is observing how well the Ion endoluminal system, a robotic tool, works for lung nodule biopsies and localization in everyday medical practice across Europe. Researchers will track 1,200 adults to see how often the tool correctly diagnoses lung nodules and how often co…

This study follows a large group of children and young adults who received radiation therapy for cancer, to see how their health and quality of life evolve over many years. By collecting medical data and blood samples in a European registry, researchers aim to identify late effec…

This study is collecting blood samples and health data from 15,000 symptom-free adults over 40 to understand what healthy aging looks like at the molecular level. By tracking participants over time, researchers hope to establish normal ranges for thousands of blood markers and id…

This study looks at the quality of life, symptom severity, and care needs of lung cancer patients who are receiving or have received immunotherapy. By analyzing questionnaires from 180 participants, researchers aim to identify factors that influence these needs, such as marital s…

This study looks at why some older adults with serious conditions like cancer or fractures become vulnerable or frail. Researchers will follow about 1500 patients to find out how common different causes of vulnerability are and how they affect outcomes like survival and quality o…

This observational study aims to identify genetic mutations in adults with advanced solid cancers who are being considered for or are already in early-phase clinical trials. By analyzing tumor and blood samples over time, researchers hope to understand how these mutations influen…

This trial asks whether five advanced AI models can match the treatment recommendations of expert tumor boards for cancer patients. Using 100 standardized synthetic cases across breast, lung, urological, digestive, and gynecological cancers, each AI and two independent tumor boar…

This study is testing whether regular heart and lung monitoring, along with blood samples, can predict side effects in people with lung cancer receiving radiation and immunotherapy. The goal is to find early warning signs of heart or lung damage before symptoms appear. The trial …

This study looks for biological markers in the blood that could help diagnose and predict the course of three serious lung conditions: COPD, idiopathic pulmonary fibrosis (IPF), and lung cancer. Researchers will analyze blood samples from 120 adults with these diseases to find li…

This study looks back at medical records of people in Colombia diagnosed with early-stage non-small cell lung cancer between 2017 and 2023. Researchers aim to understand how patients are diagnosed, how long it takes to start treatment, and what factors affect their care. By mappi…

This study tests whether having a specialist review genetic test results and guide treatment decisions can increase the use of targeted therapies for people with advanced solid tumors, including breast, lung, colorectal, and bladder cancers. Participants will have their tumor or …

This study aims to create a rapid autopsy program for people with small cell lung cancer (SCLC). Within 10 hours of death, researchers collect tumor and blood samples to study the disease's biology. The goal is to generate new cell lines and genetic data that could lead to better…

This international registry collects data on patients diagnosed with thoracic cancers (including lung cancer) while pregnant or who become pregnant during or after cancer treatment. Because these cases are rare, there is little information to guide doctors. The registry aims to d…

This study follows 600 people with lung cancer or mesothelioma to track how their tumors evolve during and after treatment. Researchers collect blood, tissue, and imaging samples every few months to understand why some cancers come back or stop responding to therapy. The goal is …

This study investigates whether measuring nitric oxide in a person's breath can predict how well they will respond to immunotherapy for advanced non-small cell lung cancer. Participants take a simple breath test before starting immunotherapy and again after four treatment cycles.…

This study looks at whether fluid rinsed from the airways during lung cancer surgery contains enough tiny particles (called extracellular vesicles) to study. Researchers want to see if these particles can help predict if non-small cell lung cancer will come back. The study involv…

This study collects blood and tumor tissue samples from people with head and neck or lung cancers to find biological markers that indicate low oxygen levels within tumors. Low-oxygen tumors tend to be more aggressive and resistant to standard treatments like radiation and chemoth…

This study looks at a standardized method for giving high-dose radiation a second time to people with solid tumors that have come back. It uses advanced imaging to better calculate radiation doses to sensitive organs like the spinal cord and gut. The goal is to track how often se…

This study follows 6,000 adults with solid tumors who are receiving immune checkpoint inhibitors as part of their routine cancer care. Researchers are tracking how long patients live and how long their disease stays under control. The goal is to learn how well these drugs work in…

This study investigates clonal hematopoiesis (CH) — small mutations in blood cells that can arise naturally or after cancer treatment — in adults receiving chemotherapy or radiation for solid tumors like breast, lung, or colorectal cancer. Researchers will collect blood, saliva, …

This study explores whether a blood test that detects circulating tumor DNA (ctDNA) can help doctors personalize treatment for people with five types of advanced cancer: non-small cell lung cancer, gastrointestinal stromal tumors, colorectal cancer, biliary tract cancer, and ovar…

This study watches for heart changes in 150 adults receiving chest radiation for lung, esophageal, breast, or thymus cancer. Researchers will check heart markers, electrical activity, and immune cells at the end of treatment and up to 3 months later. The goal is to find early sig…

This study tests a low-literacy conversation tool designed to help lung cancer patients and their doctors make treatment decisions together. Researchers will enroll 300 patients to see if the tool improves understanding, reduces confusion, and boosts confidence in choices. The fo…

This study looks back at 600 advanced lung cancer patients who received immunotherapy. Researchers will analyze their tissue samples and genetic data to find patterns linked to long-term survival. They aim to build an AI model that can predict survival from standard microscope im…

This study is tracking how the cancer drug tislelizumab is actually used in everyday European clinics for patients with advanced non-small cell or small cell lung cancer. Researchers will observe 440 participants to see treatment patterns, dosing changes, and real-world outcomes …

This study looks at fluid from around the lungs (pleural effusion) in people with non-small cell lung cancer. Researchers want to see how often important cancer markers like PD-L1, ALK, and EGFR can be found in that fluid. They will also check if the amount of fluid tested affect…

This study looks at whether a program called 'Couples Coping Together Against Cancer' is helpful and practical for people with advanced cancers like stage IV breast cancer, glioblastoma, or lung cancer, and their partners. Researchers at City of Hope will enroll 160 couples to se…

This study is collecting tumor tissue and blood samples from 800 people with lung cancer to look for changes in a gene pathway called EGFR. The goal is to better understand the DNA mutations that drive the disease. No new treatment is being tested; instead, researchers hope to id…

This study looks at 100 people with advanced solid tumors whose cancer stopped responding to immunotherapy. Researchers will take a fresh tumor sample and blood tests to compare genetic and immune differences between those who never responded and those who initially improved but …